CY1120204T1 - Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο - Google Patents

Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο

Info

Publication number
CY1120204T1
CY1120204T1 CY20181100493T CY181100493T CY1120204T1 CY 1120204 T1 CY1120204 T1 CY 1120204T1 CY 20181100493 T CY20181100493 T CY 20181100493T CY 181100493 T CY181100493 T CY 181100493T CY 1120204 T1 CY1120204 T1 CY 1120204T1
Authority
CY
Cyprus
Prior art keywords
brand
disposal
cancer treatment
solid solar
amorphic
Prior art date
Application number
CY20181100493T
Other languages
English (en)
Inventor
Patrice A. Lee
Shannon L. WINSKI
Kevin Koch
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120204(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of CY1120204T1 publication Critical patent/CY1120204T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις για τη θεραπεία του καρκίνου του εγκεφάλου. Περιγράφονται επίσης φαρμακευτικές συνθέσεις που αποτελούνται από αυτές τις ενώσεις για τη θεραπεία του καρκίνου του εγκεφάλου.
CY20181100493T 2012-03-23 2018-05-14 Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο CY1120204T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
PCT/US2013/033751 WO2013142875A1 (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Publications (1)

Publication Number Publication Date
CY1120204T1 true CY1120204T1 (el) 2018-12-12

Family

ID=48048296

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100493T CY1120204T1 (el) 2012-03-23 2018-05-14 Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
CY20211100126T CY1123837T1 (el) 2012-03-23 2021-02-16 Ενωσεις για την χρηση στη θεραπεια μεταστασεων στον εγκεφαλο σε ασθενη με καρκινο του μαστου erbb2+

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100126T CY1123837T1 (el) 2012-03-23 2021-02-16 Ενωσεις για την χρηση στη θεραπεια μεταστασεων στον εγκεφαλο σε ασθενη με καρκινο του μαστου erbb2+

Country Status (30)

Country Link
US (3) US20150110780A1 (el)
EP (4) EP4252855A3 (el)
JP (6) JP2015514075A (el)
KR (3) KR102317166B1 (el)
CN (2) CN104203279B (el)
AU (4) AU2013234921A1 (el)
CA (1) CA2867723C (el)
CL (1) CL2014002497A1 (el)
CO (1) CO7071139A2 (el)
CY (2) CY1120204T1 (el)
DK (2) DK2827900T3 (el)
ES (2) ES2855142T3 (el)
HK (1) HK1206276A1 (el)
HR (1) HRP20180659T1 (el)
HU (2) HUE037966T2 (el)
IL (3) IL234627B (el)
LT (1) LT2827900T (el)
MX (1) MX354024B (el)
MY (1) MY174883A (el)
NZ (4) NZ741615A (el)
PH (1) PH12014502032A1 (el)
PL (2) PL2827900T3 (el)
PT (2) PT3400943T (el)
RS (1) RS57140B1 (el)
RU (2) RU2018138976A (el)
SG (1) SG11201405954YA (el)
SI (2) SI2827900T1 (el)
TR (1) TR201808450T4 (el)
UA (1) UA122044C2 (el)
WO (1) WO2013142875A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852060A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
SG11201401459YA (en) 2011-10-14 2014-07-30 Array Biopharma Inc Solid dispersions of a erb2 (her2) inhibitor
EP4252855A3 (en) 2012-03-23 2023-11-15 Array Biopharma, Inc. Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
EP3592387A4 (en) * 2017-03-09 2021-03-31 The Board of Trustees of the Leland Stanford Junior University TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING THE CD47 SIGNAL PATH
MA49059A (fr) 2017-04-28 2021-03-24 Seagen Inc Traitement des cancers positifs à her2
CN112566665A (zh) * 2018-04-09 2021-03-26 莫舍·吉拉迪 用TTFields和Aurora激酶抑制剂治疗肿瘤
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
LT4084778T (lt) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai
IL293864A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
CN102432552B (zh) 2003-08-14 2016-01-20 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
CA2569132A1 (en) 2004-06-03 2005-12-22 Smithkline Beecham (Cork) Limited Cancer treatment method
CA2755268C (en) 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
BRPI0706788A2 (pt) 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
JP2010540460A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
CA2852060A1 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
SG11201401459YA (en) * 2011-10-14 2014-07-30 Array Biopharma Inc Solid dispersions of a erb2 (her2) inhibitor
EP4252855A3 (en) 2012-03-23 2023-11-15 Array Biopharma, Inc. Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer

Also Published As

Publication number Publication date
MX2014011437A (es) 2014-11-10
PL2827900T3 (pl) 2018-08-31
AU2017272232B2 (en) 2019-02-28
WO2013142875A1 (en) 2013-09-26
IL269205A (en) 2019-11-28
US20150110780A1 (en) 2015-04-23
CO7071139A2 (es) 2014-09-30
AU2013234921A1 (en) 2014-10-02
KR20210131426A (ko) 2021-11-02
JP2022190126A (ja) 2022-12-22
PH12014502032A1 (en) 2014-11-24
MY174883A (en) 2020-05-20
JP2024019526A (ja) 2024-02-09
EP3400943B1 (en) 2020-12-02
ES2855142T3 (es) 2021-09-23
US20190255051A1 (en) 2019-08-22
AU2017272232C1 (en) 2019-08-15
JP2021178820A (ja) 2021-11-18
AU2021261849A1 (en) 2021-12-02
MX354024B (es) 2018-02-08
NZ724544A (en) 2018-05-25
NZ756264A (en) 2022-09-30
EP2827900A1 (en) 2015-01-28
CN104203279B (zh) 2018-10-30
CN109223791A (zh) 2019-01-18
NZ630843A (en) 2017-01-27
SG11201405954YA (en) 2014-10-30
SI3400943T1 (sl) 2021-03-31
KR20140139009A (ko) 2014-12-04
RU2014142700A (ru) 2016-05-20
JP2015514075A (ja) 2015-05-18
RU2018138976A (ru) 2018-12-06
AU2017272232A1 (en) 2018-01-04
EP4252855A2 (en) 2023-10-04
US20230190749A1 (en) 2023-06-22
CL2014002497A1 (es) 2014-11-14
PT2827900T (pt) 2018-06-14
ES2673165T3 (es) 2018-06-20
EP2827900B1 (en) 2018-03-21
AU2019203618A1 (en) 2019-06-13
HRP20180659T1 (hr) 2018-06-01
KR102160462B1 (ko) 2020-09-28
DK3400943T3 (da) 2021-02-08
NZ741615A (en) 2019-10-25
DK2827900T3 (en) 2018-05-07
LT2827900T (lt) 2018-05-10
EP3400943A1 (en) 2018-11-14
IL261659A (en) 2018-10-31
RU2018138976A3 (el) 2022-04-08
PT3400943T (pt) 2021-02-02
IL269205B (en) 2020-06-30
US11504370B2 (en) 2022-11-22
HK1206276A1 (en) 2016-01-08
AU2019203618B2 (en) 2021-08-05
JP7404485B2 (ja) 2023-12-25
IL234627B (en) 2018-10-31
HUE037966T2 (hu) 2018-09-28
HUE053156T2 (hu) 2021-06-28
KR102317166B1 (ko) 2021-10-26
RU2672575C2 (ru) 2018-11-16
EP4252855A3 (en) 2023-11-15
PL3400943T3 (pl) 2021-06-14
JP2019081792A (ja) 2019-05-30
CN104203279A (zh) 2014-12-10
CA2867723A1 (en) 2013-09-26
JP6898960B2 (ja) 2021-07-07
SI2827900T1 (en) 2018-06-29
EP3842044A1 (en) 2021-06-30
CA2867723C (en) 2022-11-08
RS57140B1 (sr) 2018-07-31
KR102490961B1 (ko) 2023-01-19
TR201808450T4 (tr) 2018-07-23
JP2017141302A (ja) 2017-08-17
KR20200115656A (ko) 2020-10-07
CY1123837T1 (el) 2022-05-27
UA122044C2 (uk) 2020-09-10

Similar Documents

Publication Publication Date Title
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1120734T1 (el) Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
TR201901886T4 (tr) DNA-PK inhibitörleri.
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
EA201691940A1 (ru) Новые соединения
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
EA201500926A1 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EA201590987A1 (ru) Соединения и способы их применения
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
GB201209613D0 (en) New compounds
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201492002A1 (ru) Противовирусные соединения
EA201391106A1 (ru) Новые гетероциклические производные
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
GT201500069A (es) Piridinonas bicìclicas novedosas
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
EA201591451A1 (ru) Модуляторы flap